µ²ºc¦¡ |
|
¥[¤J 5 mL ª`®g¥Î¤ô¡]WFI¡^·»¸Ñ«á¡A¿@ÁY²G¿@«×¬° 5 mg rabbit-ATG /ml¡C ¬Û·í©ó¨C²~§t 25 mg/5ml ¨ß§Ü¤HÃþ¯Ý¸¢²ÓM§K¬Ì²y³J¥Õ¡]rabbit anti-human thymocyte immunoglobulin, rabbit-ATG¡^
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
¥»«~¬O¿ï¾Ü©Ê§K¬Ì§í¨î¾¯¡]§@¥Î©ó T ²O¤Ú²ÓM¡^¡A§@¥Î¾÷Âà¦p¤U¡GƒÜ¥»«~¥Dn§K¬Ì§í¨î¾÷Âà¬O³y¦¨Å餺²O¤Ú²y²M°£¡C¥»«~¥i¿ëÃѤj³¡¤À¦b²¾´Ó®É T ²ÓM¬¡¤Æ¨t²Îªº¤À¤l¡A¦p CD2¡BCD3¡BCD4¡BCD8¡BCD11a¡B CD18¡BCD25¡BHLA-DR ©M HLA class I¡CT ²ÓM¸g³æ®Ö²y©M§]¾½²ÓM¨t²Î½Õ±±ªº¸ÉÅé-¨Ì¿à©Ê·»¸Ñ©M Fc-¨Ì¿à©Ê½Õ©M§@¥Î¦b´`Àô¨t²Î¤¤³Q²M°£¡CƒÜ ¥»«~°£³y¦¨ T ²ÓM²M°£¥H¥~¡A¤]¯à¤Þµo¨ä¥L²O¤Ú²yªº§K¬Ì§í¨î¤ÏÀ³¡C Åé¥~¸ÕÅ礤¡A§C¿@«×ªº Thymoglobuline 0.1 mg/mL ¥i¬¡¤Æ T ²ÓM©M«P¶i CD4+¡BCD8+¨t¦C²ÓM¼W¥Í¡A¨ë¿E IL-2¡BIFN-ƒ×ªº¦X¦¨©M CD25ªºªí²{¡C¦¹²ÓM¤Àµõ¬¡©Ê¥Dn¸g¥Ñ CD2 ³~®|¡C¦b°ª¿@«×®É¡A¥»«~ÂǪýÂ_ IFN-ƒ×©M CD25 ¦X¦¨ªº«áÂà¿ý´Á¡]¦ý«D´î¤Ö IL-2 ¤Àªc¡^¶i¦Ó§í¨î²O¤Ú²y¹ï¨ä¥L²ÓM¤Àµõ쪺¼W¥Í¤ÏÀ³¡CƒÜ ¦bÅé¥~¸ÕÅ礤¡AThymoglobuline ¨Ã¤£¬¡¤Æ B ²ÓM¡C ¨Ï¥Î Thymoglobuline ªvÀøªº±wªÌµo¥Í B ²ÓM²O¤ÚÀùªº¦MÀI©Ê§C¡A¥i¥H¤U¦C¾÷Âà¸ÑÄÀ¡G ¥»«~¤£¬¡¤Æ B ²ÓM¡A¦]¦¹¼ß²ÓM¨Ã¤£¤À¤Æ¡C §Ü B ²ÓM©MÃþ²O¤Ú²y¥À²ÓM®è¼W¥Í¡C
|
¾AÀ³¯g |
|
¹w¨¾¤ÎªvÀø²¾´Óª«¤§±Æ¥¸¡q¦pµÇŦ²¾´Ó¡B¤ßŦ²¾´Ó¤Î°©Åè²¾´Ó¡r¡AÄY«¦A¥Í¤£¨}©Ê³h¦å¡C »¡©ú¡G¾¹©x²¾´Ó¡G¹w¨¾©ÎªvÀøµÇŦ¡B¤ßŦ¡B¯ØŦ¤Î¨xŦ²¾´Ó¤â³N«á¤§±Æ¥¸¡C¦å²G¬ì¡GªvÀø¦A¥Í¤£¨}©Ê³h¦å¡AªvÀø²¾´Óª«¤Ï±J¥D¤ÏÀ³¡C
|
¥Îªk¥Î¶q |
|
ÀR¯ßª`®g¡C 1. ¹w¨¾«æ©Ê±Æ¥¸¡G1~1.5mg/kg/day¡C 2. ¹w¨¾µÇŦ¡B¯ØŦ©Î¨xŦ²¾´Ó¤â³N«á¤§±Æ¥¸«ùÄò 2~9¤Ñ¡C 3. ¹w¨¾¤ßŦ²¾´Ó¤â³N«á¤§±Æ¥¸«ùÄò 2~5 ¤Ñ¡C¤ßŦ²¾´Ó²Ö¿n¾¯¶q¬°2~7.5mg/kg¡C 4. ¨ä¥L¾¹©x²¾´Ó²Ö¿n¾¯¶q¬° 2~13.5mg/kg¡C 5. ªvÀø«æ©Ê±Æ¥¸¡G1.5mg/kg/day «ùÄò 3~14 ¤Ñ¡A²Ö¿n¾¯¶q¬° 4.5~21mg/kg¡C 6. ªvÀøÃþ©T¾J§Ü©Ê¡A«æ©Ê²¾´Óª«¤Ï±J¥D¯e¯f¡G¾¯¶q¨ÌÓÅé¦Ó©w¡A«Øij 2~5mg/kg/day «ùÄò 5 ¤Ñ¡C 7. ¦A¥Í¤£¨}©Ê³h¦å¡G2.5~3.5mg/kg/day «ùÄò 5 ¤Ñ¡A©Îµ¹²Ö¿n¾¯¶q 12.5~17.5mg/kg¡C
§ë¤©¤èªk¥»ÃÄ¥ÑÂå®v¨Ï¥Î¡C ¥»«~³q±`»P¨ä¥L§K¬Ì§í¨îÃĪ«¦X¨Ö¥Î©óªvÀøÀøµ{¡C ¦b¿éª`¥»«~¤§«eÀ³¥ý§ë¤©ÀR¯ßª`®gªºÃþ©T¾J¤Î§Ü²Õ´ÓiÃĪ«¡C ·»¸Ñ«áªº¿@ÁY²G¬°¼á²M©Î±a¦³»´·Lªº¨Å¥ú¦â¡C ¸g¥Ñ°ª¬y¶qªº¤jÀR¯ß¿éª`¡A½Õ¾ã¿éª`³t²v¨ÏÁ`¿éª`®É¶¡¦Ü¤Ö¤j©ó4¤p®É¡C
|
°Æ§@¥Î |
|
²O¤Ú²y´î¤Ö¯g¡B¶Ý¤¤©Ê¥Õ¦å²y´î¤Ö¯g©M¦å¤pªO´î¤Ö¯g¡Bµo¿N¡C
|
¥æ¤¬§@¥Î |
|
©M¥H¤UÃĪ«¨Ö¥Î®É»Ýª`·N¡G cyclosporine¡Btacrolimus¡Bmycophenolate mofetil¡G²£¥Í¹L«×§K¬Ì§í¨îªº¦MÀI¡A¨Ï²O¤Ú¼W¥Íªº¦MÀI©Ê´£°ª¡C
¬¡©Ê´î¬r¬Ì]¡G¥i¯à²£¥Í¥þ¨©Ê·P¬V¦ÓP¦º¡C¹ï©ó¦]¼ç¦b¯e¯f¦Ó§K¬Ì¥\¯à¤£¥þªº±wªÌ(¦p¦A¥Í¤£¨}©Ê³h¦å)¡A¦¹¦MÀI©Ê¥i¯à¼W¥[¡C
|
¸T§Ò |
|
1.¬¡°Ê©Ê¡B«æ©Ê©ÎºC©Ê·P¬VªÌÀ³ÁקK¶i¦æ¥ô¦ó§K¬Ì§í¨îÀøµ{¡C 2.¤wª¾¹ï¨ß¤l³J¥Õ©Î¬O¥»«~½á§Î¾¯¦¨¤À¹L±ÓªÌ¡C
|
µ¹¥I³W©w |
|
8.1.4.Immunoglobulin¡]¦p¡GThymoglobuline inj¡^(90/11/1¡B96/2/1¡B97/8/1¡B99/2/1¡B109/4/1)¡G 1.²Å¦X¤U¦C¾AÀ³¯g¯f±wÀ˪þ¯f¾úºKn¡]µù©ú¶EÂ_¡B¬ÛÃöÀˬd³ø§i¤Î¼Æ¾Ú¡BÅé«¡B¦~ÄÖ¡B©Ê§O¡B¯f¥v) (1)ÄY«¦A¥Í¤£¨}©Ê³h¦å¸g¶Ç²Î¤èªkªvÀøµL®Ä¥B¤£¾A¦X§@°©Åè²¾´Ó¤§¯f¨Ò¡C (2)¾¹©x²¾´Ó¯f±w¨ÖµoÄY«¤§«æ©Ê±Æ¥¸¤ÏÀ³¡C (3)©w©ó²§Åé³y¦å·F²ÓM²¾´Ó¤§´ÓÅé§Ü±J¥D¯e¯f¡]graft versus host disease¡^¤§¹w¨¾»PªvÀø¡C(109/4/1) (4)¤ßŦ²¾´Ó¯f¤H¨Ï¥Î©I§l¾¹¡A¨Ã¥i¯à¨ÖµoµÇ¥\¯à¤£¥þªÌ¡C (5)Thymoglobuline inj.¥i¥Î©ó¹w¨¾¤ßŦ¡BµÇŦ²¾´Ó¤Þ°_¤§«æ©Ê±Æ¥¸¡C(109/4/1) (6)§@¬°²§Åé³y¦å·F²ÓM²¾´Ó«e¤§±ø¥óÀøªk(109/4/1)¡C
|
ª`·N¨Æ¶µ |
|
ÃÄ«~½Õ°t¤Î³B¸m¯S§Oª`·N¨Æ¶µ¡G ±N¯»¥½¥H 5 mL ªºµLµßª`®g¥Î¤ô·»¸Ñ¡A©Ò±oªº·»²G¿@«×¬° 5 mg ³J¥Õ½è/mL¡A¨ä¬°¼á²M©Î»´·L¨Å¥ú¦â¡C ½Õ°t¹Lµ{À³²Å¦XÀu¨}¾Þ§@·Ç«h³W©w¡A¯S§O»Ýnª`·NµLµß¾Þ°µ¤âÄò¡C ·»¸Ñ«áªºÃÄ«~¥²¶·¥Ø´ú¬O§_§t¦³·L²É¤ÎÅܦâ¡C¦pªG¤´¦³·L²É¡A«ùÄò»´»´±ÛÂà²~¨ª½¦Ü·L²É®ø¥¢¡C¦pªG·L²É«ùÄò¦s¦b¡A«h¥á±ó¦¹²~ÃÄ¡C·»¸Ñ«áªºÃÄ«~«Øij¥ß§Y¨Ï¥Î¡C¨C²~ÃĶȨѳ榸¨Ï¥Î¡Cµø¨C¤éªº¾¯¶q¦Ó©w¡A¤]³\»Ýn·»¸Ñ³\¦h²~ Thymoglobuline ¯»¥½¡C ¨M©w»Ý¥Îªº²~¼Æ«á¡A¨ú³Ì±µªñªº²~¼Æ¡C¬°ÁקK¤£¤p¤ßµ¹¤©§t¦³·L²Éªº·»¸Ñ²G¡A«Øij¥H¤º¸m 0.22 £gm Âo¾¹ªºª`®gºÞ½uµ¹ÃÄ¡C¨C¤éªº¾¯¶q¥H¿éª`·»²G¡]¥Í²z¹ÆQ¤ô©Î 5%¸²µå¿}²G¡^µ}ÄÀ¦¨Á`Åé¿n 50~500 mL¡]³q±` 50 mL/vial¡^¡C µ}ÄÀ«áªºÃÄ«~¶·¦b¦P¤@¤Ñµ¹ÃÄ¡C
|
ĵ»y |
|
¦]¬°¤wª¾Thymoglobuline¿éª`´Á¶¡¥i¯àµo¥Íªº¤£¨}¨Æ¥ó¡A¯S§O¬O²ÓM¿E¯ÀÄÀ©ñ¯gÔ¸s¡A«Øij¯f¤H©óThymoglobulineªvÀø´Á¶¡¤£¥i¶}¨®©Î¾Þ§@¾÷±ñ¡C
Thymoglobuline¿éª`¤§¯S®í¦Ò¶q: ´N¦p¨ä¥L¥ô¦óÃÄ«~ªº¿éª`¡A·|¦³¿éª`³¡¦ìªº§½³¡¤ÏÀ³¡A¥]¬A¯kµh¡B¸~µÈ¤Îµo¬õ¡C
|
¹L¶q³B²z |
|
¤£¤p¤ß¹L¶q¨Ï¥Î¥i¯à¾ÉP¥Õ¦å²y´î¤Ö¯g©M¦å¤pªO´î¤Ö¯g¡C³o¨Ç¤ÏÀ³¦b¾¯¶q½Õ¾ã©Î°±¤îªvÀø«á§Y¥i¦^´_¡C ¥»«~¨S¦³«ú§Ü¾¯¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
¬[¶J´Á¡G °Ñ¨£¥]¸Ë¤W¼Ð¥Ü¡C «Øijµ}ÄÀ«á¥ß§Y¨Ï¥Î¡A¥HÁקK·L¥Íª«¦Ã¬V¡C µM¦Ó¥»«~¦b¨Ï¥Î®ÉÅã¥Ü¨ä¤Æ¾Ç©Ê¤Îª«²z©Ê¦b 2 ~8 ¢XC ¤U¥iéw 24 ¤p®É¡C Àx¦sª`·N¨Æ¶µ¡G §NÂÃÀx¦s¦b 2~8 ¢J¡C¥»«~«·s½Õ»s«á½Ð¥ß§Y¨Ï¥Î¡CÃÄ«~¹B¿é´Á¶¡«Øij·Å«×«O«ù¦b 2 ~8 ¢XC¡A¦ý´Á¶¡Yµu¼Èªº¶W·Å¹F¨ì 25¢XC ¤´¤£·|¼vÅT¥»«~«~½è¡C
|